Back

Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies

1 September 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Treatment of transthyretin amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mohd Turzo Rahman

Flushing Hospital and Medical Center, Flushing (United States of America)

7 More presentations in this session

Presentation thumbnail
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Diagnostic, therapeutic and prognostic implications of carpal tunnel syndrome and spinal stenosis in wild-type transthyretin cardiac amyloidosis.
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis
Doctor T. Tsampras (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Which patients did recent trials in transthyretin amyloid cardiomyopathy select? - insights from a prospective patient registry
Doctor L. Schmid (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
Doctor F. Cappelli (Florence, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of transthyretin amyloidosis

The Event

Event poster

ESC Congress 2025

1 September 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
thumbnail
Congress Presentation
Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systemic review and meta-analysis.
thumbnail
Congress Presentation
Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources